glucagon-like peptide-1
Peptideexperimental
Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption. The initial product GLP-1 (1–37) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (7–36) amide and GLP-1 (7–37). Active GLP-1 protein secondary structure includes two α-helices from amino acid position 13–20 and 24–35 separated by a linker region. — Wikipedia
Clinical trial activity
44 trials · 40 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
4
Phase 3
2
Phase 4
3
Earliest trial started Feb 1, 2004 (NCT00612625)
Timeline
Indications
Approved for
Studied for
- Affect · Early Phase 1
- Bariatric Surgery · Early Phase 1
- Blood Glucose · Phase 1/Phase 2
- Body Weight · Early Phase 1
- Coronary Disease · Phase 4
- Critical Illness · Phase 2
- Diabetes Mellitus · Phase 1
- Diabetes Mellitus, Type 1 · Early Phase 1
- Diabetes Mellitus, Type 2 · Phase 4
- Healthy Volunteers · Phase 2/Phase 3
- Heart Failure · Phase 1
- Hemorrhage · Phase 1/Phase 2
- Hyperglycemia · Phase 1
- Hypoglycemia · Phase 2
- Immune System Diseases · Early Phase 1
- Inflammation · Early Phase 1
- Insulin Resistance · Early Phase 1
- Insulin Secretion · Phase 1
- Intestinal Failure · Phase 1/Phase 2
- Longevity · Early Phase 1
- Pain Management · Early Phase 1
- Pancreatic Diseases · Phase 1
- Quality of Life · Early Phase 1
- Short Bowel Syndrome · Phase 1/Phase 2
- Urination Disorders · Early Phase 1
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C- Mol. weight
- 3169.55 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGlucagon-like peptide-1 ↗
- ChEMBLCHEMBL4594475 ↗
- ChEMBLCHEMBL1240772 ↗
Also known as
- glp-1
- glp-1
- glucagon like peptide-1
- glucagon like peptide-1
- glucagon-like peptide-1
- glucagon-like peptide-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06722560 | N/A | Dec 2, 2024 | University of Southern Denmark |
| NCT07092605 | Early Phase 1 (Phase 1) | Nov 1, 2024 | AgelessRx |
| NCT06194955 | N/A | Jan 4, 2023 | University of Copenhagen |
| NCT04355832 | Early Phase 1 (Phase 1) | May 31, 2020 | University of Maryland |
| NCT04232605 | N/A | Jan 9, 2020 | University of Copenhagen |
| NCT04133922 | Early Phase 1 (Phase 1) | Oct 14, 2019 | American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Virginia |
| NCT04337268 | N/A | Apr 1, 2019 | University of Copenhagen, University of Southern Denmark |
| NCT02333591 | Phase 4 | Jul 1, 2016 | University of Copenhagen |
| NCT03414333 | N/A | Jun 29, 2016 | University of Pisa |
| NCT02738151 | Phase 4 | May 19, 2016 | Sanofi |
| NCT02550548 | Phase 1 | Apr 21, 2016 | Duke University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT02537834 | Phase 4 | Aug 1, 2015 | Kowa, Sanofi |
| NCT02591849 | N/A | Oct 1, 2014 | Osaka University |
| NCT02129179 | Phase 1 | Jun 1, 2014 | Papworth Hospital NHS Foundation Trust |
| NCT02130778 | Early Phase 1 (Phase 1) | Apr 1, 2014 | Merck, University of Zagreb |
| NCT01988545 | N/A | Nov 30, 2013 | Køge Hospital, University of Copenhagen |
| NCT01858896 | Early Phase 1 (Phase 1) | Jul 1, 2013 | University of Maryland |
| NCT03195257 | N/A | Nov 17, 2012 | University of Copenhagen |
| NCT01739283 | N/A | Jul 31, 2012 | University of Copenhagen |
| NCT01689051 | N/A | Mar 31, 2012 | Danish Heart Foundation, University of Copenhagen |
Showing 20 of 44 trials
Page 1 / 3
Organizations
Research & Development (40)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 14 | 14 | 2 | 2004 |
| Merck | For profit | 5 | 0 | 2 | 2006 |
| Aarhus University | Academic/Hospital | 4 | 4 | 2 | 2005 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 4 | 0 | 1 | 2008 |
| Sanofi | For profit | 2 | 1 | 1 | 2015 |
| University of Basel | Academic/Hospital | 2 | 0 | 2 | 2006 |
| University of Bern | Academic/Hospital | 2 | 2 | 2 | 2006 |
| University of Maryland | Academic/Hospital | 2 | 2 | 1 | 2013 |
| University of Southern Denmark | Academic/Hospital | 2 | 1 | 1 | 2019 |
| Washington University in St. Louis | Academic/Hospital | 2 | 2 | 1 | 2008 |
| AgelessRx | Academic/Hospital | 1 | 1 | 1 | 2024 |
| American Diabetes Association | Academic/Hospital | 1 | 0 | 1 | 2019 |
| BTG | For profit | 1 | 1 | 1 | 2008 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Danish Heart Foundation | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| German Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Government of Denmark | Government | 1 | 0 | 1 | 2011 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| International Neuroscience Institute Hanover | Academic/Hospital | 1 | 0 | 1 | 2008 |
40 organizations
Page 1 / 2